Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalo Therapeutics, Inc.AVTX · Entity 4936 | Chief Commercial Officer | January 04, 2022 | January 06, 2022 |
| Cartesian Therapeutics, Inc.SELB · Entity 6015 | Chief Commercial Officer | January 02, 2020 | January 06, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalo Therapeutics, Inc.
Report date January 04, 2022 · Filed January 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.70 · Expires 2032-01-04 | Direct | 400,000 |
Reported balance
After 2022-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-04 · Grant · Acquired 400,000 · Balance 400,000 F1: The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments over the following 36 months, subject to the reporting person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments over the following 36 months, subject to the reporting person's continued service on each such vesting date.
Cartesian Therapeutics, Inc.
Report date January 02, 2020 · Filed January 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2030-01-01 | Direct | 100,000 |
Reported balance
After 2020-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-02 · Grant · Acquired 100,000 · Balance 100,000 F1: This option will vest as to 25% on January 2, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest as to 25% on January 2, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 04, 2022 Filed Jan 6, 2022 16:19 UTC | Avalo Therapeutics, Inc. AVTX · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001062993-22-000731 · form4.xml · derivative · entry 1 Smolinski Stephen · CIK 0001721031 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2032-01-04 F1 · derivative.exercise_date: The stock option will vest over four years, with the first 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal monthly installments over the following 36 months, subject to the reporting person's continued service on each such vesting date. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 20:08 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001453687-20-000015 · wf-form4_157835931999296.xml · derivative · entry 1 Smolinski Stephen · CIK 0001721031 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-01-01 F1 · derivative.exercise_date: This option will vest as to 25% on January 2, 2021. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| October 07, 2019 Filed Oct 9, 2019 16:20 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001453687-19-000148 · wf-form4_157065241992844.xml · derivative · entry 1 Smolinski Stephen · CIK 0001721031 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2029-10-06 F1 · derivative.exercise_date: This option shall vest as to 50% of the shares on October 7, 2020, and the remaining 50% of the shares on October 7, 2021. Read SEC document |
| August 20, 2019 Filed Aug 20, 2019 16:32 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantCommon Stock | 13,812 | $1.81 | $24,999.72 |
DisclosureSEC source: 0001453687-19-000125 · wf-form4_156633315653823.xml · nonDerivative · entry 1 Smolinski Stephen · CIK 0001721031 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,812 Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 16:21 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $2.60 Strike: $2.60 | $260,000.00 |
DisclosureSEC source: 0001453687-19-000013 · wf-form4_154698246209632.xml · derivative · entry 1 Smolinski Stephen · CIK 0001721031 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-01-06 F1 · derivative.exercise_date: This option will vest as to 25% on January 7, 2020. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 19:05 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001638599-18-000678 · doc4_5479.xml · derivative · entry 1 Smolinski Stephen · CIK 0001721031 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on June 15, 2019. The remainder of the shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| November 17, 2017 Filed Nov 20, 2017 16:09 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $10.23 | $0.00 |
DisclosureSEC source: 0001638599-17-001155 · doc4_5082.xml · derivative · entry 1 Smolinski Stephen · CIK 0001721031 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2027-11-16 F1 · derivative.exercise_date: This option vests as to 25% of the shares on October 26, 2018. The remainder of the shares will vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.